
CorMedix Inc. – NASDAQ:CRMD
CorMedix stock price today
CorMedix stock price monthly change
CorMedix stock price quarterly change
CorMedix stock price yearly change
CorMedix key metrics
Market Cap | 499.37M |
Enterprise value | 167.95M |
P/E | -6.62 |
EV/Sales | 2567.86 |
EV/EBITDA | -5.56 |
Price/Sales | 3218.73 |
Price/Book | 3.82 |
PEG ratio | -4.96 |
EPS | -0.93 |
Revenue | N/A |
EBITDA | -53.75M |
Income | -50.23M |
Revenue Q/Q | N/A |
Revenue Y/Y | 426.39% |
Profit margin | -45409.9% |
Oper. margin | -46819.91% |
Gross margin | 94.29% |
EBIT margin | -46819.91% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCorMedix stock price history
CorMedix stock forecast
CorMedix financial statements
Jun 2023 | 0 | -11.27M | |
---|---|---|---|
Sep 2023 | 0 | -9.74M | |
Dec 2023 | 304.11K | -14.75M | -4851.54% |
Mar 2024 | 0 | -14.46M |
Dec 2023 | 304.11K | -14.75M | -4851.54% |
---|---|---|---|
Mar 2024 | 0 | -14.46M | |
Oct 2025 | 18M | -2.87M | -15.97% |
Dec 2025 | 21.95M | -1.15M | -5.24% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 57032780 | 7.98M | 13.99% |
---|---|---|---|
Sep 2023 | 91429120 | 8.22M | 9% |
Dec 2023 | 82059957 | 11.91M | 14.52% |
Mar 2024 | 68023742 | 10.01M | 14.72% |
Jun 2023 | -8.57M | -2.38M | 5.35M |
---|---|---|---|
Sep 2023 | -8.69M | -586.86K | 42.89M |
Dec 2023 | -10.74M | 597.79K | 467.65K |
Mar 2024 | -17.31M | 8.94M | -97.11K |
CorMedix alternative data
Aug 2023 | 40 |
---|---|
Sep 2023 | 40 |
Oct 2023 | 40 |
Nov 2023 | 40 |
Dec 2023 | 40 |
Jan 2024 | 40 |
Feb 2024 | 40 |
Mar 2024 | 40 |
Apr 2024 | 40 |
May 2024 | 40 |
Jun 2024 | 82 |
Jul 2024 | 82 |
CorMedix other data
Period | Buy | Sel |
---|---|---|
Dec 2023 | 6000 | 0 |
Mar 2024 | 13561 | 0 |
Nov 2024 | 0 | 140027 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | ZELNICK KAUFMAN BETH officer: Chief Legal Officer | Common Stock | 12,500 | N/A | N/A | ||
Option | ZELNICK KAUFMAN BETH officer: Chief Legal Officer | Restricted Stock Units | 12,500 | N/A | N/A | ||
Option | HURLBURT ELIZABETH officer: EVP | Stock Option (Right to Buy Common Stock) | 3 | $1.45 | $4 | ||
Option | HURLBURT ELIZABETH officer: EVP | Common Stock | 8,169 | $8.3 | $67,803 | ||
Option | HURLBURT ELIZABETH officer: EVP | Common Stock | 3 | $1.45 | $4 | ||
Sale | HURLBURT ELIZABETH officer: EVP | Common Stock | 140,027 | $11.18 | $1,565,642 | ||
Option | HURLBURT ELIZABETH officer: EVP | Stock Option (Right to Buy Common Stock) | 9,888 | $5.63 | $55,669 | ||
Option | HURLBURT ELIZABETH officer: EVP | Stock Option (Right to Buy Common Stock) | 8,169 | $8.3 | $67,803 | ||
Option | HURLBURT ELIZABETH officer: EVP | Stock Option (Right to Buy Common Stock) | 34,467 | $4.08 | $140,625 | ||
Option | HURLBURT ELIZABETH officer: EVP | Common Stock | 25,000 | $3.47 | $86,750 |
Patent |
---|
Application Filling date: 19 May 2020 Issue date: 1 Apr 2021 |
Application Filling date: 5 Oct 2020 Issue date: 25 Mar 2021 |
Application ANTIMICROBIAL WOUND CLOSURE MATERIALS, INCLUDING ANTIMICROBIAL SUTURES, AND METHOD FOR CLOSING A WOUND USING THE SAME Filling date: 31 Dec 2019 Issue date: 17 Dec 2020 |
Application Filling date: 13 Jun 2019 Issue date: 30 Jan 2020 |
Grant Utility: Antimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same Filling date: 18 Aug 2016 Issue date: 31 Dec 2019 |
Application Filling date: 3 Sep 2019 Issue date: 19 Dec 2019 |
Application Filling date: 28 Aug 2019 Issue date: 19 Dec 2019 |
Application Filling date: 28 Aug 2019 Issue date: 19 Dec 2019 |
Grant Filling date: 28 Mar 2017 Issue date: 19 Nov 2019 |
Quarter | Transcript |
---|---|
Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 12 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of CorMedix stock today?
One share of CorMedix stock can currently be purchased for approximately $13.06.
-
When is CorMedix's next earnings date?
Unfortunately, CorMedix's (CRMD) next earnings date is currently unknown.
-
Does CorMedix pay dividends?
No, CorMedix does not pay dividends.
-
How much money does CorMedix make?
CorMedix has a market capitalization of 499.37M.
-
What is CorMedix's stock symbol?
CorMedix Inc. is traded on the NASDAQ under the ticker symbol "CRMD".
-
What is CorMedix's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CorMedix?
Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CorMedix's key executives?
CorMedix's management team includes the following people:
- Dr. Phoebe Mounts Esq. Executive Vice President, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal(age: 75, pay: $523,080)
- Ms. Elizabeth Masson-Hurlburt Executive Vice President & Head of Clinical Operations(age: 46, pay: $463,850)
- Dr. Matthew T. David M.D. Interim Chief Executive Officer, Executive Vice President & Chief Financial Officer(age: 47, pay: $441,960)
-
How many employees does CorMedix have?
As Jul 2024, CorMedix employs 82 workers, which is 105% more then previous quarter.
-
When CorMedix went public?
CorMedix Inc. is publicly traded company for more then 15 years since IPO on 13 May 2010.
-
What is CorMedix's official website?
The official website for CorMedix is cormedix.com.
-
Where are CorMedix's headquarters?
CorMedix is headquartered at 300 Connell Drive, Berkeley Heights, NJ.
-
How can i contact CorMedix?
CorMedix's mailing address is 300 Connell Drive, Berkeley Heights, NJ and company can be reached via phone at +90 85179500.
CorMedix company profile:

CorMedix Inc.
cormedix.comNASDAQ
82
Biotechnology
Healthcare
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Berkeley Heights, NJ 07922
CIK: 0001410098
ISIN: US21900C3088
CUSIP: 21900C308